24 November 2017
News and Views
Links and Services
The latest study of Gastroenterology evaluates medications and the risk of esophageal adenocarcinoma in patients with Barrett's.
Limited evidence suggests that proton pump inhibitors (PPI), nonsteroidal anti-inflammatory drugs
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors